Maximum Tolerated Dose of Lapatinib When Given With Carboplatin for Recurrent Ovarian Cancer

Part of paid clinical trials in Birmingham, Alabama.

Sponsor
University of Alabama at Birmingham
Study ID
NCT00317434
Phase
PHASE1
Status
Terminated

Conditions

Eligibility Criteria

Sex
FEMALE
Age
19 Years - 90 Years
Healthy Volunteers
Not accepted

Interventions

  • lapatinib — DRUG

Study Details

The purpose of this study is to determine the maximum tolerated dose of Lapatinib with Carboplatin AUC 6 in patients with platinum sensitive recurrent ovarian or primary peritoneal carcinoma and to determine the nature and degree of toxicity of Lapatinib in combination with carboplatin AUC 6 in this cohort of patients.

Key Dates

Start date
Nov 30, 2005
Status verified
Dec 2009
Primary completion
Mar 31, 2007
Completion
Apr 30, 2007

Study Design

Enrollment
12 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Primary Outcome Measure

MTD of Lapatinib measured in cohorts of 3-6 patients each

Locations (2)

FacilityCityStateZIPSite coordinators
University of Alabama at BirminghamBirminghamAlabama35205-
Indiana University School of MedicineIndianapolisIndiana48202-

Find similar trials in Birmingham, AL

By condition
Ovarian cancer
By specialty
OncologyGynecologic oncologyWomen's health
By research site
University of Alabama at Birmingham· Birmingham, ALIndiana University School of Medicine· Indianapolis, IN

Related Studies